Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 18/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239082 | 0.87 | P2RX4 (0.73) | P2RX4 | |
| SCHEMBL30297308 | 0.87 | P2RX4 (0.73) | P2RX4 | |
| SCHEMBL16267449 | 0.81 | P2RX4 (0.54) | P2RX4NPC1RAB9A | |
| SCHEMBL30297307 | 0.81 | P2RX4 (0.67) | P2RX4RAB9A | |
| SCHEMBL16239173 | 0.81 | P2RX4 (0.67) | P2RX4 | |
| SCHEMBL16238989 | 0.81 | P2RX4 (0.67) | P2RX4RAB9A | |
| Hydrochloric Acid SCHEMBL16267545 | 0.80 | P2RX4 (0.66) | P2RX4 | |
| Hydrochloric Acid SCHEMBL30297283 | 0.80 | P2RX4 (0.66) | P2RX4 | |
| SCHEMBL16239101 | 0.79 | P2RX4 (0.51) | P2RX4 | |
| SCHEMBL16238983 | 0.79 | P2RX4 (0.57) | P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250375456-A1 | AGENT FOR PREVENTING OR TREATING RESPIRATORY DISEASE | NIPPON CHEMIPHAR CO (JP) | 2025-12-11 | — | — | US | claimed |
| US-20250241927-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | NIPPON CHEMIPHAR CO (JP) | 2025-07-31 | — | — | US | claimed |
| EP-4501357-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | Takasaki University of Health and Welfare (JP) | 2025-02-05 | — | — | EP | claimed |
| WO-2024177158-A1 | SOLID DISPERSION OF COMPOUND HAVING P2X4 RECEPTOR ANTAGONISM | 日本ケミファ株式会社 | 2024-08-29 | — | — | WO | claimed |
| EP-4408432-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-07 | — | — | EP | claimed |
| EP-4410310-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-07 | — | — | EP | claimed |
| US-11918589-B2 | Medicament for treatment of multiple sclerosis | NIPPON CHEMIPHAR CO., LTD. (JP) | 2024-03-05 | — | — | US | claimed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | claimed |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-09-07 | — | — | US | claimed |
| WO-2023052518-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2023-04-06 | — | — | WO | claimed |
| EP-4129296-A1 | DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | Università di Pisa (IT) | 2023-02-08 | — | — | EP | claimed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | claimed |
| EP-3848051-A1 | MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY | Nippon Chemiphar Co., Ltd. (JP) | 2021-07-14 | — | — | EP | claimed |
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-04-29 | — | — | US | claimed |
| EP-3766497-A1 | DRUG FOR TREATING COUGH | Nippon Chemiphar Co., Ltd. (JP) | 2021-01-20 | — | — | EP | claimed |
| US-20210000840-A1 | MEDICAMENT FOR TREATING COUGH | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-01-07 | — | — | US | claimed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | claimed |
| EP-2803662-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-03-01 | — | — | EP | claimed |
| US-9382236-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-07-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375456-A1 | AGENT FOR PREVENTING OR TREATING RESPIRATORY DISEASE | P2RX5, P2RX3, P2RX2 | P2RX4 7/4885NPC1 685/4885CASP3 3870/4885 |
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | TRPM4, TRPM7, P2RX3 | P2RX4 5/4885NPC1 925/4885CASP3 1039/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885NPC1 2397/4885CASP3 4027/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | P2RX4 6/4885NPC1 2397/4885CASP3 4027/4885 |
| US-11918589-B2 | Medicament for treatment of multiple sclerosis | P2RX3, TRPM4, P2RX4 | P2RX4 3/4885NPC1 1013/4885CASP3 1113/4885 |
| US-20210000840-A1 | MEDICAMENT FOR TREATING COUGH | P2RX4, P2RX3, P2RX5 | P2RX4 1/4885NPC1 545/4885CASP3 1273/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | P2RX4 15/4885NPC1 809/4885CASP3 3056/4885 |
| US-20230277552-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH ALLERGIC REACTION | P2RX5, P2RX3, P2RX2 | P2RX4 4/4885NPC1 741/4885CASP3 4035/4885 |
| US-20250241927-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | P2RX3, TRPV1, P2RX2 | P2RX4 5/4885NPC1 1663/4885CASP3 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.